Access to essential medicines in India boosted by drug price caps

8 December 2015

The results have started coming in. Accessibility to essential medicines in India by the poor has improved dramatically after the government capped the prices of 530 drugs under the price monitoring mechanism, reports The Pharma Letter’s India correspondent.

Around 47 formulations for cancer, 20 for AIDS/HIV, six for diabetes and 53 for cardiovascular diseases have had their prices reduced recently.

As a result of reduction in the prices of scheduled medicines under price control, the price benefit accrued to the public is estimated to the extent of around $363 million, India's Parliament was informed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK